Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency ...

Investing.com -- Equillium Inc (NASDAQ:EQ)股价暴跌12.4%，此前这家生物技术公司宣布计划将加密货币纳入其财政储备策略，这与其开发自身免疫和炎症疾病治疗方案的核心业务有显著偏离。 这家总部位于圣地亚哥的公司透露，将开始持有数字货币作为其财务和增长目标的一部分，同时继续推进其生物技术使命。首席执行官Bruce Steel表示，此举是为了"多样化、流动性和长期 ...

As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny ...

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft ...

Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Shares of Equillium, Inc. (EQ) have been struggling lately and have lost 52.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the ...

Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Equillium, Inc. (EQ) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

Equillium Inc. is forging ahead with regulatory plans for itolizumab in first-line treatment of patients with acute graft-vs.-host disease (GVHD), despite a phase III disappointment. Shares of the La ...

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease Treatment with itolizumab did not improve complete ...

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis Feb. 06, 2025 8:00 AM ET Equillium, Inc. (EQ) ...

Equillium Inc. plans to continue on its own with itolizumab – now the top pipeline priority – as Ono Pharmaceutical Co. Ltd. Is letting expire the option for rights to the monoclonal antibody, ...